Andrew Althouse, Discover and Read the Best of Twitter Threads by @ADAlthousePhD

Andrew Althouse

ADAlthousePhD

After last week’s thread on efficacy stopping in RCT’s explaining that i) trials that stop early for efficacy tend to slightly overestimate treatment effect but ii) this does not mean

As promised last week, here is a thread to explore and explain some beliefs about interim analyses and efficacy stopping in randomized controlled trials. Brief explanation of motivation for this

Having one of those mornings where you realize that it's sometimes a lot more work to be a good scientist/analyst than a bad one.(Explanation coming...) Processing some source data that

With the REMAP-CAP paper out in @JAMA_current today, I wonder if @statberry or @RogerJLewis would be willing to do a Twitter thread trying to summarize how the REMAP approach worked

The NEJM compassionate-use remdesivir data was always sort of a "passing curiosity while we await trial data" but it's disappointing that the analysis was done wrong.But, it offers an opportunity

Scrolling through some SAS help pages for their different graphics and laughed out loud at this:"When used in the business domain, often there is a desire for a graph with